| Brandei K Wingard, MD | |
|
9 Healthcare Drive, Suite 105, Biddeford, ME 04005 | |
| (207) 282-3666 | |
| (207) 282-4281 |
| Full Name | Brandei K Wingard |
|---|---|
| Gender | Female |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 17 Years |
| Location | 9 Healthcare Drive, Biddeford, Maine |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033318753 | NPI | - | NPPES |
| AA316117 | Other | ME | HARVARD PILGRIM |
| 7840316 | Other | ME | CIGNA |
| 1033318753 | Other | ME | ANTHEM |
| 1033318753 | Medicaid | ME | |
| 9221840 | Other | ME | AETNA |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northern Light Mercy Hospital | Portland, ME | Hospital |
| Northern Light Inland Hospital | Waterville, ME | Hospital |
| Southern Maine Health Care | Biddeford, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Martin's Point Health Care | 5991776635 | 90 |
| Mercy Hospital | 6103737812 | 207 |
| Eastern Maine Healthcare Systems Inland Hospital | 6305817503 | 75 |
News Archive
Diversionary Therapy Technologies is pleased to announce one of the first U.S. sales of its groundbreaking ditto device, which is clinically proven to lower anxiety and treatment times while improving pediatric patient outcomes. UMC Health System, based in Lubbock, Texas, has purchased and will be offering this revolutionary aid to children at the hospital.
The annual economic cost of the nearly 16,000 premature births linked to air pollution in the United States has reached $4.33 billion, according to a report by scientists at NYU Langone Medical Center.
Patients with bipolar disorder may be eligible for a new clinical research study comparing two medications - quetiapine, a widely prescribed second-generation antipsychotic mood-stabilizing medication, and lithium, the gold-standard mood stabilizer.
NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully demonstrated the ability of the NexACT technology to deliver insulin and other large molecule drugs such as Taxol subcutaneously, in a depot-like fashion (or slow release) over a 24 hour period from a single injection.
Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, the results of a Phase IIb/III trial show.
› Verified 7 days ago
| Entity Name | Mercy Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629078712 PECOS PAC ID: 6103737812 Enrollment ID: O20040217000943 |
News Archive
Diversionary Therapy Technologies is pleased to announce one of the first U.S. sales of its groundbreaking ditto device, which is clinically proven to lower anxiety and treatment times while improving pediatric patient outcomes. UMC Health System, based in Lubbock, Texas, has purchased and will be offering this revolutionary aid to children at the hospital.
The annual economic cost of the nearly 16,000 premature births linked to air pollution in the United States has reached $4.33 billion, according to a report by scientists at NYU Langone Medical Center.
Patients with bipolar disorder may be eligible for a new clinical research study comparing two medications - quetiapine, a widely prescribed second-generation antipsychotic mood-stabilizing medication, and lithium, the gold-standard mood stabilizer.
NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully demonstrated the ability of the NexACT technology to deliver insulin and other large molecule drugs such as Taxol subcutaneously, in a depot-like fashion (or slow release) over a 24 hour period from a single injection.
Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, the results of a Phase IIb/III trial show.
› Verified 7 days ago
| Entity Name | Central Maine Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689653487 PECOS PAC ID: 2567379563 Enrollment ID: O20040324000441 |
News Archive
Diversionary Therapy Technologies is pleased to announce one of the first U.S. sales of its groundbreaking ditto device, which is clinically proven to lower anxiety and treatment times while improving pediatric patient outcomes. UMC Health System, based in Lubbock, Texas, has purchased and will be offering this revolutionary aid to children at the hospital.
The annual economic cost of the nearly 16,000 premature births linked to air pollution in the United States has reached $4.33 billion, according to a report by scientists at NYU Langone Medical Center.
Patients with bipolar disorder may be eligible for a new clinical research study comparing two medications - quetiapine, a widely prescribed second-generation antipsychotic mood-stabilizing medication, and lithium, the gold-standard mood stabilizer.
NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully demonstrated the ability of the NexACT technology to deliver insulin and other large molecule drugs such as Taxol subcutaneously, in a depot-like fashion (or slow release) over a 24 hour period from a single injection.
Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, the results of a Phase IIb/III trial show.
› Verified 7 days ago
| Entity Name | Mainehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790265502 PECOS PAC ID: 7517860588 Enrollment ID: O20040701000166 |
News Archive
Diversionary Therapy Technologies is pleased to announce one of the first U.S. sales of its groundbreaking ditto device, which is clinically proven to lower anxiety and treatment times while improving pediatric patient outcomes. UMC Health System, based in Lubbock, Texas, has purchased and will be offering this revolutionary aid to children at the hospital.
The annual economic cost of the nearly 16,000 premature births linked to air pollution in the United States has reached $4.33 billion, according to a report by scientists at NYU Langone Medical Center.
Patients with bipolar disorder may be eligible for a new clinical research study comparing two medications - quetiapine, a widely prescribed second-generation antipsychotic mood-stabilizing medication, and lithium, the gold-standard mood stabilizer.
NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully demonstrated the ability of the NexACT technology to deliver insulin and other large molecule drugs such as Taxol subcutaneously, in a depot-like fashion (or slow release) over a 24 hour period from a single injection.
Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, the results of a Phase IIb/III trial show.
› Verified 7 days ago
| Entity Name | Southern Maine Health Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659392819 PECOS PAC ID: 0143208348 Enrollment ID: O20040713001060 |
News Archive
Diversionary Therapy Technologies is pleased to announce one of the first U.S. sales of its groundbreaking ditto device, which is clinically proven to lower anxiety and treatment times while improving pediatric patient outcomes. UMC Health System, based in Lubbock, Texas, has purchased and will be offering this revolutionary aid to children at the hospital.
The annual economic cost of the nearly 16,000 premature births linked to air pollution in the United States has reached $4.33 billion, according to a report by scientists at NYU Langone Medical Center.
Patients with bipolar disorder may be eligible for a new clinical research study comparing two medications - quetiapine, a widely prescribed second-generation antipsychotic mood-stabilizing medication, and lithium, the gold-standard mood stabilizer.
NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully demonstrated the ability of the NexACT technology to deliver insulin and other large molecule drugs such as Taxol subcutaneously, in a depot-like fashion (or slow release) over a 24 hour period from a single injection.
Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, the results of a Phase IIb/III trial show.
› Verified 7 days ago
| Entity Name | Eastern Maine Healthcare Systems Inland Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376579557 PECOS PAC ID: 6305817503 Enrollment ID: O20040802001656 |
News Archive
Diversionary Therapy Technologies is pleased to announce one of the first U.S. sales of its groundbreaking ditto device, which is clinically proven to lower anxiety and treatment times while improving pediatric patient outcomes. UMC Health System, based in Lubbock, Texas, has purchased and will be offering this revolutionary aid to children at the hospital.
The annual economic cost of the nearly 16,000 premature births linked to air pollution in the United States has reached $4.33 billion, according to a report by scientists at NYU Langone Medical Center.
Patients with bipolar disorder may be eligible for a new clinical research study comparing two medications - quetiapine, a widely prescribed second-generation antipsychotic mood-stabilizing medication, and lithium, the gold-standard mood stabilizer.
NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully demonstrated the ability of the NexACT technology to deliver insulin and other large molecule drugs such as Taxol subcutaneously, in a depot-like fashion (or slow release) over a 24 hour period from a single injection.
Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, the results of a Phase IIb/III trial show.
› Verified 7 days ago
| Entity Name | Martin's Point Health Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366474611 PECOS PAC ID: 5991776635 Enrollment ID: O20040804001702 |
News Archive
Diversionary Therapy Technologies is pleased to announce one of the first U.S. sales of its groundbreaking ditto device, which is clinically proven to lower anxiety and treatment times while improving pediatric patient outcomes. UMC Health System, based in Lubbock, Texas, has purchased and will be offering this revolutionary aid to children at the hospital.
The annual economic cost of the nearly 16,000 premature births linked to air pollution in the United States has reached $4.33 billion, according to a report by scientists at NYU Langone Medical Center.
Patients with bipolar disorder may be eligible for a new clinical research study comparing two medications - quetiapine, a widely prescribed second-generation antipsychotic mood-stabilizing medication, and lithium, the gold-standard mood stabilizer.
NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully demonstrated the ability of the NexACT technology to deliver insulin and other large molecule drugs such as Taxol subcutaneously, in a depot-like fashion (or slow release) over a 24 hour period from a single injection.
Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, the results of a Phase IIb/III trial show.
› Verified 7 days ago
| Entity Name | Maine Medical Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073527388 PECOS PAC ID: 9335043967 Enrollment ID: O20050401000844 |
News Archive
Diversionary Therapy Technologies is pleased to announce one of the first U.S. sales of its groundbreaking ditto device, which is clinically proven to lower anxiety and treatment times while improving pediatric patient outcomes. UMC Health System, based in Lubbock, Texas, has purchased and will be offering this revolutionary aid to children at the hospital.
The annual economic cost of the nearly 16,000 premature births linked to air pollution in the United States has reached $4.33 billion, according to a report by scientists at NYU Langone Medical Center.
Patients with bipolar disorder may be eligible for a new clinical research study comparing two medications - quetiapine, a widely prescribed second-generation antipsychotic mood-stabilizing medication, and lithium, the gold-standard mood stabilizer.
NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully demonstrated the ability of the NexACT technology to deliver insulin and other large molecule drugs such as Taxol subcutaneously, in a depot-like fashion (or slow release) over a 24 hour period from a single injection.
Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, the results of a Phase IIb/III trial show.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brandei K Wingard, MD One Medical Center Drive, Biddeford, ME 04005 Ph: (207) 282-9080 | Brandei K Wingard, MD 9 Healthcare Drive, Suite 105, Biddeford, ME 04005 Ph: (207) 282-3666 |
News Archive
Diversionary Therapy Technologies is pleased to announce one of the first U.S. sales of its groundbreaking ditto device, which is clinically proven to lower anxiety and treatment times while improving pediatric patient outcomes. UMC Health System, based in Lubbock, Texas, has purchased and will be offering this revolutionary aid to children at the hospital.
The annual economic cost of the nearly 16,000 premature births linked to air pollution in the United States has reached $4.33 billion, according to a report by scientists at NYU Langone Medical Center.
Patients with bipolar disorder may be eligible for a new clinical research study comparing two medications - quetiapine, a widely prescribed second-generation antipsychotic mood-stabilizing medication, and lithium, the gold-standard mood stabilizer.
NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully demonstrated the ability of the NexACT technology to deliver insulin and other large molecule drugs such as Taxol subcutaneously, in a depot-like fashion (or slow release) over a 24 hour period from a single injection.
Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, the results of a Phase IIb/III trial show.
› Verified 7 days ago
Dr. Peter G Kachavos, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 46 Barra Rd, Biddeford, ME 04005 Phone: 207-282-3349 | |
Jennifer Cutone, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 30 W Cole Rd, Biddeford, ME 04005 Phone: 207-282-3349 Fax: 207-282-6099 | |
Dr. Eva Zaslavsky, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 26 W Cole Rd, Biddeford, ME 04005 Phone: 207-294-5800 Fax: 207-294-5801 | |
Thomas Courtney, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2 Medical Center Dr, Suite 3, Biddeford, ME 04005 Phone: 207-283-8406 | |
Nadeem S Ali, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 30 West Cole Road, Biddeford, ME 04005 Phone: 207-282-3349 Fax: 207-282-6099 | |
Dr. Richard Martin Kahn, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 9 Healthcare Drive, Suite 209, Biddeford, ME 04005 Phone: 207-283-6408 Fax: 207-286-1327 | |
Christopher Patrick Blomberg, D.O. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 9 Healthcare Dr Ste 105, Biddeford, ME 04005 Phone: 207-282-3666 |